当前位置:首页 > 成功案例 > 杭州觅瑞

杭州觅瑞


杭州觅瑞

图片.png

MiRXES是一家总部位于新加坡的生物技术公司,致力于将研究成果转化为世界领先的多种癌症早期检测。公司在新加坡、美国、日本和中国拥有研发、制造和临床诊断业务,在全球拥有销售和分销网络。

MiRXES的旗舰产品是GASTROClear,这是世界上第一个用于早期检测胃癌的分子血液检测,能够检测出90%左右的Ⅰ、Ⅱ期癌症患者

MiRXES将继续建立一个全面的癌症组合,包括肺癌和甲状腺癌(2022年)、结直肠癌和乳腺癌(2023年)、肝癌和卵巢癌(2024年)的早期检测测试。同时,正在建立一个精确的肿瘤学组合,为整个患者旅程提供临床见解。

MiRXES2014年从A*STAR的生物处理技术研究所(Bioprocessing Technology Institute)剥离出来,将一种基于qPCR的行业领先的microRNA检测技术商业化。ID3EAL发现工具和工作流程已被全球顶级学术和行业合作伙伴采用,并得到世界上第一个microRNA碱基诊断行业标准的支持。

MiRXES is a Singapore-headquartered biotechnology company that translates research discoveries to deliver world-leading multi-cancer early detection. They have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and Chinaand have sales and distribution networks worldwide.

Their flagship product is GASTROClear, the worlds first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. 

They will continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). They are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.

MiRXES was spun off from A*STARs Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Their ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the worlds first industry standard for microRNA-base diagnostics.


https://mirxes.com/

0.172684s